Germany - Pharmaceuticals

Description

The purpose of the present announcement is the conclusion of agreements with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book V. The invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 of the German Medicines Act. It is not an open procedure according to § 15 VgV in conjunction with § 119 Section 3 GWB, but a publication of the invitation to conclude/accede to/for discount agreements with conditions that are fixed and non-negotiable for all participants, including the amount of the discount. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act may become contractual partners.
The purpose of the present announcement is the conclusion of agreements on the active ingredient "Pegfilgrastim (ATC code: L03AA13)" with pharmaceutical companies within the meaning of § 130a Section 8 Sentence 1 of the German Social Security Code, Book 5 (SGB V) (discount agreements). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/for discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contract partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active substance "Betamethasone/ Salicylic acid, pharmaceutical form: LOE (ATC code: D07XC01)" with pharmaceutical companies within the meaning of § 130a para. 8 sentence 1 Social Security Code, Book 5 (SGB V) (discount contracts). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/for discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contract partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active ingredient "Risperidone, pharmaceutical form: LSE (ATC Code: N05AX08)" with pharmaceutical companies within the meaning of § 130a para. 8 sentence 1 of the German Social Security Code, Book 5 (SGB V) (discount agreements). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/to discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contract partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active substance "Salbutamol, pharmaceutical form: IHP (ATC-Code: R03AC02)" with pharmaceutical companies in the sense of § 130a para. 8 sentence 1 Social Security Code, fifth book (SGB V) (discount contracts). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/to discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contract partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active ingredient "Furosemide, pharmaceutical form: REK (ATC code: C03CA01)" with pharmaceutical companies within the meaning of § 130a para. 8 sentence 1 of the German Social Security Code, Book 5 (SGB V) (discount agreements). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/to discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contracting partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active substance "Ritonavir (ATC-Code: J05AE03)" with pharmaceutical companies in the sense of § 130a para. 8 sentence 1 Social Security Code, fifth book (SGB V) (discount contracts). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs as defined in § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/for discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contracting partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The closing date for the receipt of applications is 5.11.2022. In any case, the contracts shall end on 31.12.2022. The purpose of the present announcement is the conclusion of agreements on the active substance "Sevelamer hydrochloride (ATC Code: V03AE02)" with pharmaceutical companies within the meaning of § 130a para. 8 sentence 1 of the German Social Security Code, Book 5 (SGB V) (discount agreements). According to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/accede to/for discount agreements with conditions fixed and non-negotiable for all participants, including the amount of the discount. The relevant information under IV.1.1) is only due to the system of this form. An unlimited number of pharmaceutical contractors or employee associations of pharmaceutical contractors within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contractual partners. The information under II.2.5) is due to the systematics of this publication form. The conclusion of the contract or accession to the contract is effected by sending the required completed self-declarations or evidence as well as the contract or contracts either:a) signed by hand (written form pursuant to Section 126 BGB) by post orb) provided with a qualified electronic signature (Section 126a BGB) by e-mail to openhouse.rabattvertrag2020-10@kbs.de. The earliest date for the conclusion of the contract is 1 January 2021 if the contract and the required declarations or evidence are received by the KBS by 5 December 2020 at the latest. The contract therefore starts on the first day of the month following the month in which the contract and the required declarations or evidence are received by the CAB, provided that they are received by the 5th of each month; otherwise on the first day of the month after next. The contracts end automatically, without the need for termination, as soon as the contracting partner(s) for the active substance(s) or the active substance combination(s) has/have been determined in a formal award procedure. The deadline for the receipt of applications is 5.11.2022. In any case, the contracts end on 31.12.2022.

Opportunity closing date

05 November 2022

Value of contract

to be confirmed